Mechanisms of estrogen signaling and gene expression via GPR30

Molecular and Cellular Endocrinology

Volumn 308, Issue 1-2, 2009, Pages 32-38

  Prossnitz, Eric R ^a   Maggiolini, Marcello ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Estrogen; Estrogen receptor; GPER; GPR30; Transcription

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 30; GONADORELIN; PROTEIN C FOS; UNCLASSIFIED DRUG;

BREAST CANCER; CALCIUM MOBILIZATION; CARCINOGENESIS; CELL PROLIFERATION; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ESTROGEN BINDING; GENE EXPRESSION REGULATION; GERM CELL TUMOR; HUMAN; HYPERALGESIA; MENOPAUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; THYROID CANCER; TRANSCRIPTION INITIATION;

ANIMALS; ESTROGENS; GENE EXPRESSION; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 67349105361     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.03.026     Document Type: Review

References (83)

1. Ahola T.M., Alkio N., Manninen T., and Ylikomi T. Progestin and G protein-coupled receptor 30 inhibit mitogen-activated protein kinase activity in MCF-7 breast cancer cells. Endocrinology 143 (2002) 4620-4626
2. Ahola T.M., Manninen T., Alkio N., and Ylikomi T. G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology 143 (2002) 3376-3384
3. Ahola T.M., Purmonen S., Pennanen P., Zhuang Y.H., Tuohimaa P., and Ylikomi T. Progestin upregulates G-protein-coupled receptor 30 in breast cancer cells. Eur. J. Biochem. 269 (2002) 2485-2490
4. Albanito L., Lappano R., Madeo A., Chimento A., Prossnitz E.R., Cappello A.R., Dolce V., Abonane S., Pezzi V., and Maggiolini M. G protein-coupled receptor 30 and estrogen receptor alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells. Environ. Health Perspect. 116 (2008) 1648-1655
5. Albanito L., Madeo A., Lappano R., Vivacqua A., Rago V., Carpino A., Oprea T.I., Prossnitz E.R., Musti A.M., Ando S., and Maggiolini M. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 67 (2007) 1859-1866
6. Albanito L., Sisci D., Aquila S., Brunelli E., Vivacqua A., Madeo A., Lappano R., Pandey D.P., Picard D., Mauro L., Ando S., and Maggiolini M. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology 149 (2008) 3799-3808
7. Alyea R.A., Laurence S.E., Kim S.H., Katzenellenbogen B.S., Katzenellenbogen J.A., and Watson C.S. The roles of membrane estrogen receptor subtypes in modulating dopamine transporters in PC-12 cells. J. Neurochem. 106 (2008) 1525-1533
8. Baquedano M.S., Saraco N., Berensztein E., Pepe C., Bianchini M., Levy E., Goni J., Rivarola M.A., and Belgorosky A. Identification and developmental changes of aromatase and estrogen receptor expression in prepubertal and pubertal human adrenal tissues. J. Clin. Endocrinol. Metab. 92 (2007) 2215-2222
9. Beatson. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet ii (1896) 104-107
10. Bhola N.E., and Grandis J.R. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front. Biosci. 13 (2008) 1857-1865
11. Boivin B., Vaniotis G., Allen B.G., and Hebert T.E. G protein-coupled receptors in and on the cell nucleus: a new signaling paradigm?. J. Recept. Signal Transduct. Res. 28 (2008) 15-28
12. Bologa C.G., Revankar C.M., Young S.M., Edwards B.S., Arterburn J.B., Kiselyov A.S., Parker M.A., Tkachenko S.E., Savchuck N.P., Sklar L.A., Oprea T.I., and Prossnitz E.R. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol. 2 (2006) 207-212
13. Bouskine A., Nebout M., Mograbi B., Brucker-Davis F., Roger C., and Fenichel P. Estrogens promote human testicular germ cell cancer through a membrane-mediated activation of extracellular regulated kinase and protein kinase A. Endocrinology 149 (2008) 565-573
14. Carmeci C., Thompson D.A., Ring H.Z., Francke U., and Weigel R.J. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 45 (1997) 607-617
15. Das S.K., Tan J., Raja S., Halder J., Paria B.C., and Dey S.K. Estrogen targets genes involved in protein processing, calcium homeostasis, and Wnt signaling in the mouse uterus independent of estrogen receptor-alpha and -beta. J. Biol. Chem. 275 (2000) 28834-28842
16. Dennis M.K., Burai R., Ramesh C., Petrie W.K., Alcon S.N., Nayak T., Bologa C., Leitao A., Brailoiu E., Deliu E., Dun N.J., Sklar L.A., Hathaway H.J., Arterburn J.B., Oprea T.O., and Prossnitz E.R. In vivo effects of a GPR30 antagonist. Nat. Chem. Biol. 5 (2009) 421-427
17. DeWire S.M., Ahn S., Lefkowitz R.J., and Shenoy S.K. Beta-arrestins and cell signaling. Annu. Rev. Physiol. 69 (2007) 483-510
18. Eddy E.M., Washburn T.F., Bunch D.O., Goulding E.H., Gladen B.C., Lubahn D.B., and Korach K.S. Targeted disruption of the estrogen receptor gene in male mice causes alteration of spermatogenesis and infertility. Endocrinology 137 (1996) 4796-4805
19. Edwards D.P. Regulation of signal transduction pathways by estrogen and progesterone. Annu. Rev. Physiol. 67 (2005) 335-376
20. Fan W., Yanase T., Morinaga H., Gondo S., Okabe T., Nomura M., Hayes T.B., Takayanagi R., and Nawata H. Herbicide atrazine activates SF-1 by direct affinity and concomitant co-activators recruitments to induce aromatase expression via promoter II. Biochem. Biophys. Res. Commun. 355 (2007) 1012-1018
21. Fan W., Yanase T., Morinaga H., Gondo S., Okabe T., Nomura M., Komatsu T., Morohashi K., Hayes T.B., Takayanagi R., and Nawata H. Atrazine-induced aromatase expression is SF-1 dependent: implications for endocrine disruption in wildlife and reproductive cancers in humans. Environ. Health Perspect. 115 (2007) 720-727
22. Filardo E.J. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J. Steroid Biochem. Mol. Biol. 80 (2002) 231-238
23. Filardo E.J., Graeber C.T., Quinn J.A., Resnick M.B., Giri D., DeLellis R.A., Steinhoff M.M., and Sabo E. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin. Cancer Res. 12 (2006) 6359-6366
24. Filardo E.J., Quinn J.A., Bland K.I., and Frackelton Jr. A.R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 14 (2000) 1649-1660
25. Filardo E.J., Quinn J.A., Frackelton Jr. A.R., and Bland K.I. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endocrinol. 16 (2002) 70-84
26. Filardo E.J., and Thomas P. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol. Metab. 16 (2005) 362-367
27. Freeman M. Feedback control of intercellular signalling in development. Nature 408 (2000) 313-319
28. Fu X.D., and Simoncini T. Extra-nuclear signaling of estrogen receptors. IUBMB Life 60 (2008) 502-510
29. Haas E., Bhattacharya I., Brailoiu E., Damjanovic M., Brailoiu G.C., Gao X., Mueller-Guerre L., Marjon N.A., Gut A., Minotti R., Meyer M.R., Amann K., Ammann E., Perez-Dominguez A., Genoni M., Clegg D.J., Dun N.J., Resta T.C., Prossnitz E.R., and Barton M. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ. Res. 104 (2009) 288-291
30. Harrington W.R., Kim S.H., Funk C.C., Madak-Erdogan Z., Schiff R., Katzenellenbogen J.A., and Katzenellenbogen B.S. Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol. Endocrinol. 20 (2006) 491-502
31. Henderson B.E., Ross R.K., Pike M.C., and Casagrande J.T. Endogenous hormones as a major factor in human cancer. Cancer Res. 42 (1982) 3232-3239
32. Heneweer M., van den Berg M., and Sanderson J.T. A comparison of human H295R and rat R2C cell lines as in vitro screening tools for effects on aromatase. Toxicol. Lett. 146 (2004) 183-194
33. Hsieh Y.C., Yu H.P., Frink M., Suzuki T., Choudhry M.A., Schwacha M.G., and Chaudry I.H. G protein-coupled receptor 30-dependent protein kinase A pathway is critical in nongenomic effects of estrogen in attenuating liver injury after trauma-hemorrhage. Am. J. Pathol. 170 (2007) 1210-1218
34. Jacobs M.N., and Lewis D.F. Steroid hormone receptors and dietary ligands: a selected review. Proc. Nutr. Soc. 61 (2002) 105-122
35. Jensen E.V., Desombre E.R., Hurst D.J., Kawashima T., and Jungblut P.W. Estrogen-receptor interactions in target tissues. Arch. Anat. Microsc. Morphol. Exp. 56 (1967) 547-569
36. Kamanga-Sollo E., White M.E., Chung K.Y., Johnson B.J., and Dayton W.R. Potential role of G-protein-coupled receptor 30 (GPR30) in estradiol-17beta-stimulated IGF-I mRNA expression in bovine satellite cell cultures. Domest. Anim. Endocrinol. 35 (2008) 254-262
37. Kanda N., and Watanabe S. 17Beta-estradiol enhances the production of nerve growth factor in THP-1-derived macrophages or peripheral blood monocyte-derived macrophages. J. Invest. Dermatol. 121 (2003) 771-780
38. Kanda N., and Watanabe S. 17Beta-estradiol inhibits oxidative stress-induced apoptosis in keratinocytes by promoting Bcl-2 expression. J. Invest. Dermatol. 121 (2003) 1500-1509
39. Kanda N., and Watanabe S. 17Beta-estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression. J. Invest. Dermatol. 123 (2004) 319-328
40. Kuhn J., Dina O.A., Goswami C., Suckow V., Levine J.D., and Hucho T. GPR30 estrogen receptor agonists induce mechanical hyperalgesia in the rat. Eur. J. Neurosci. 27 (2008) 1700-1709
41. Lange C.A., Gioeli D., Hammes S.R., and Marker P.C. Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer. Annu. Rev. Physiol. 69 (2007) 171-199
42. Lefkowitz R.J. Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol. Sci. 25 (2004) 413-422
43. Levin E.R. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol. Endocrinol. 17 (2003) 309-317
44. Ma L., and Pei G. Beta-arrestin signaling and regulation of transcription. J. Cell Sci. 120 (2007) 213-218
45. MacGregor J.I., and Jordan V.C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 50 (1998) 151-196
46. Madak-Erdogan Z., Kieser K.J., Kim S.H., Komm B., Katzenellenbogen J.A., and Katzenellenbogen B.S. Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Mol. Endocrinol. 22 (2008) 2116-2127
47. Maggiolini M., Vivacqua A., Fasanella G., Recchia A.G., Sisci D., Pezzi V., Montanaro D., Musti A.M., Picard D., and Ando S. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J. Biol. Chem. 279 (2004) 27008-27016
48. Mårtensson U.E., Salehi S.A., Windahl S., Gomez M.F., Sward K., Daszkiewicz-Nilsson J., Wendt A., Andersson N., Hellstrand P., Grande P.O., Owman C., Rosen C.J., Adamo M.L., Lundquist I., Rorsman P., Nilsson B.O., Ohlsson C., Olde B., and Leeb-Lundberg L.M. Deletion of the G protein-coupled receptor GPR30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology 150 (2009) 687-698
49. Moore F.D., Woodrow S.I., Aliapoulios M.A., and Wilson R.E. Carcinoma of the breast. A decade of new results with old concepts. N. Engl. J. Med. 277 (1967) 411-416
50. Moriarty K., Kim K.H., and Bender J.R. Minireview: estrogen receptor-mediated rapid signaling. Endocrinology 147 (2006) 5557-5563
51. Muller R.E., Johnston T.C., Traish A.M., and Wotiz H.H. Studies on the mechanism of estradiol uptake by rat uterine cells and on estradiol binding to uterine plasma membranes. Adv. Exp. Med. Biol. 117 (1979) 401-421
52. O'Dowd B.F., Nguyen T., Marchese A., Cheng R., Lynch K.R., Heng H.H., Kolakowski Jr. L.F., and George S.R. Discovery of three novel G-protein-coupled receptor genes. Genomics 47 (1998) 310-313
53. Otto C., Rohde-Schulz B., Schwarz G., Fuchs I., Klewer M., Brittain D., Langer G., Bader B., Prelle K., Nubbemeyer R., and Fritzemeier K.H. GPR30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology 149 (2008) 4846-4856
54. Otto C., Fuchs I., Kauselmann G., Kern H., Zevnik B., Andreasen P., Schwarz G., Altmann H., Klewer M., Schoor M., Vonk R., and Fritzemeier K.H. GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol. Reprod. 80 (2009) 34-41
55. Owman C., Blay P., Nilsson C., and Lolait S.J. Cloning of human cDNA encoding a novel heptahelix receptor expressed in Burkitt's lymphoma and widely distributed in brain and peripheral tissues. Biochem. Biophys. Res. Commun. 228 (1996) 285-292
56. Pandey D.P., Lappano R., Albanito L., Madeo A., Maggiolini M., and Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J. 28 (2009) 523-532
57. Pang Y., Dong J., and Thomas P. Estrogen signaling characteristics of Atlantic croaker G protein-coupled receptor 30 (GPR30) and evidence it is involved in maintenance of oocyte meiotic arrest. Endocrinology 149 (2008) 3410-3426
58. Pasqualini J.R., Gelly C., Nguyen B.L., and Vella C. Importance of estrogen sulfates in breast cancer. J. Steroid Biochem. 34 (1989) 155-163
59. Persson I., Yuen J., Bergkvist L., and Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int. J. Cancer 67 (1996) 327-332
60. Prossnitz E.R., Arterburn J.B., Smith H.O., Oprea T.I., Sklar L.A., and Hathaway H.J. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu. Rev. Physiol. 70 (2008) 165-190
61. Prossnitz E.R., Sklar L.A., Oprea T.I., and Arterburn J.B. GPR30: a novel therapeutic target in estrogen-related disease. Trends Pharmacol. Sci. 29 (2008) 116-123
62. Razandi M., Pedram A., Park S.T., and Levin E.R. Proximal events in signaling by plasma membrane estrogen receptors. J. Biol. Chem. 278 (2003) 2701-2712
63. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., and Prossnitz E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307 (2005) 1625-1630
64. Roberge M., Hakk H., and Larsen G. Atrazine is a competitive inhibitor of phosphodiesterase but does not affect the estrogen receptor. Toxicol. Lett. 154 (2004) 61-68
65. Romano N., Lee K., Abraham I.M., Jasoni C.L., and Herbison A.E. Non-classical estrogen modulation of presynaptic GABA terminals modulates calcium dynamics in gonadotropin-releasing hormone (GnRH) neurons. Endocrinology 149 (2008) 5335-5344
66. Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J. Cell. Physiol. 213 (2007) 589-602
67. Sanderson J.T., Letcher R.J., Heneweer M., Giesy J.P., and van den Berg M. Effects of chloro-s-triazine herbicides and metabolites on aromatase activity in various human cell lines and on vitellogenin production in male carp hepatocytes. Environ. Health Perspect. 109 (2001) 1027-1031
68. Sirianni R., Chimento A., Ruggiero C., De Luca A., Lappano R., Ando S., Maggiolini M., and Pezzi V. The novel estrogen receptor, G protein-coupled receptor 30, mediates the proliferative effects induced by 17beta-estradiol on mouse spermatogonial GC-1 cell line. Endocrinology 149 (2008) 5043-5051
69. Smith H.O., Leslie K.K., Singh M., Qualls C.R., Revankar C.M., Joste N.E., and Prossnitz E.R. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am. J. Obstet. Gynecol. 196 (2007) 386.e1-386.e11
70. Starek A. Estrogens and organochlorine xenoestrogens and breast cancer risk. Int. J. Occup. Med. Environ. Health 16 (2003) 113-124
71. Sukocheva O., Wadham C., Holmes A., Albanese N., Verrier E., Feng F., Bernal A., Derian C.K., Ullrich A., Vadas M.A., and Xia P. Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J. Cell Biol. 173 (2006) 301-310
72. Takada Y., Kato C., Kondo S., Korenaga R., and Ando J. Cloning of cDNAs encoding G protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem. Biophys. Res. Commun. 240 (1997) 737-741
73. Teng J., Wang Z.Y., Prossnitz E.R., and Bjorling D.E. The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation. Endocrinology 149 (2008) 4024-4034
74. Tennant M.K., Hill D.S., Eldridge J.C., Wetzel L.T., Breckenridge C.B., and Stevens J.T. Chloro-s-triazine antagonism of estrogen action: limited interaction with estrogen receptor binding. J. Toxicol. Environ. Health 43 (1994) 197-211
75. Thomas P., Pang Y., Filardo E.J., and Dong J. Identity of an estrogen membrane receptor coupled to a G-protein in human breast cancer cells. Endocrinology 146 (2005) 624-632
76. van Leeuwen F.E., Benraadt J., Coebergh J.W., Kiemeney L.A., Gimbrere C.H., Otter R., Schouten L.J., Damhuis R.A., Bontenbal M., Diepenhorst F.W., et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343 (1994) 448-452
77. Vivacqua A., Bonofiglio D., Albanito L., Madeo A., Rago V., Carpino A., Musti A.M., Picard D., Ando S., and Maggiolini M. 17b-Estradiol, genistein and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein-coupled receptor GPR30. Mol. Pharmacol. 70 (2006) 1414-1423
78. Vivacqua A., Bonofiglio D., Recchia A.G., Musti A.M., Picard D., Ando S., and Maggiolini M. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17b-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol. Endocrinol. 20 (2006) 631-646
79. Wang C., Dehghani B., Li Y., Kaler L.J., Proctor T., Vandenbark A.A., and Offner H. Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1. J. Immunol. 182 (2009) 3294-3303
80. Wang C., Dehghani B., Magrisso I.J., Rick E.A., Bonhomme E., Cody D.B., Elenich L.A., Subramanian S., Murphy S.J., Kelly M.J., Rosenbaum J.S., Vandenbark A.A., and Offner H. GPR30 contributes to estrogen-induced thymic atrophy. Mol. Endocrinol. 22 (2008) 636-648
81. Wang C., Prossnitz E.R., and Roy S.K. Expression of GPR30 in the hamster ovary: differential regulation by gonadotropins and steroid hormones. Endocrinology 148 (2007) 4853-4864
82. Wang C., Prossnitz E.R., and Roy S.K. G protein-coupled receptor 30 expression is required for estrogen stimulation of primordial follicle formation in the hamster ovary. Endocrinology 149 (2008) 4452-4461
83. Waterhouse J., Muir C., Shanmugaratnam K., and Powel J. Cancer Incidence in Five Continents (1982), International Agency for Research on Cancer, Lyons, France pp. 185-198